HOME >> BIOLOGY >> NEWS
New tuberculosis antibiotic may shorten treatment time, fight drug-resistant strains

This release is also available in French.

A new antibiotic shows promise, thus far in mice, for treating tuberculosis much faster than current drugs do, scientists report. Additional evidence indicates that the antibiotic may work against multidrug-resistant strains of the tuberculosis bug. Studies in healthy human volunteers have indicated that the drug is safe for humans to take, and further human studies are currently underway.

These findings, by Koen Andries of Johnson & Johnson Pharmaceutical Research and Development, LLC in Beerse, Belgium and colleagues, will appear online in the 9 December Science Express, part of the journal Science, published by AAAS, the nonprofit science society.

Globally, tuberculosis is second only to AIDS as a leading cause of death from infectious disease, causing approximately two million deaths per year. The tuberculosis and HIV epidemics fuel one another; at least 11 million adults are infected with both pathogens, according to the Global Alliance for TB Drug Development.

No new tuberculosis-specific drugs have been discovered in the last 40 years, and emerging strains of the bacterium that are resistant to multiple drugs are an increasingly worrisome problem. The current treatment for drug-sensitive tuberculosis recommended by the World Health Organization consists of a cocktail of drugs that must be taken for six to nine months.

"The world desperately needs a new tuberculosis drug that can combat resistant strains of the bacterium and that is easier for patients to take. The evidence thus far suggests that this new drug lead may be up to both tasks, which is encouraging news for global health," said Katrina Kelner, Deputy Editor, life sciences, at Science.

"If this drug is ultimately approved for humans, it could lead to a change in treatment paradigm for tuberculosis," Andries said.

The dr
'"/>

Contact: Jessica Lawrence-Hurt
jlawrenc@aaas.org
1-202-326-7088
American Association for the Advancement of Science
9-Dec-2004


Page: 1 2 3 4

Related biology news :

1. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
2. Handicapping tuberculosis may be the way to a better vaccine
3. Developing a more effective vaccine for tuberculosis
4. Why is long-term therapy required to cure tuberculosis?
5. UA researchers identify new adherence factor, Pili, produced by tuberculosis
6. Shorter tuberculosis therapies could lead to substantial reductions in cases and deaths
7. Pitt phage hunter takes on tuberculosis
8. Cost-effectiveness of treating multidrug-resistant tuberculosis
9. New potential drug target in tuberculosis
10. National Institutes of Health funds $13.7 million for Texas tuberculosis study
11. Einstein researchers find potential new drugs for tuberculosis

Post Your Comments:
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
(Date:3/3/2015)... March 3, 2015  Rosa & Co. LLC, a ... and simulation research, today announced it has two posters ... for Clinical Pharmacology and Therapeutics meeting in ... Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... a poster describing a quantitative systems pharmacology approach for ...
(Date:3/3/2015)... 03, 2015 Genedata, a leading ... and life science research, today announced that Pfizer ... platform for use at Pfizer biopharma research and ... is supporting Pfizer’s global deployment and roll out ... for Therapeutic Innovation (CTI), and Pharmaceutical Sciences groups. ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...
(Date:3/3/2015)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of ... on protecting the microbiome, announced today that Jeffrey Riley ... 27th Annual ROTH Conference being held on March 8-11, 2015 ... Dana Point, CA. Mr. Riley is ... p.m. (Pacific Time). A live webcast of Synthetic ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
Cached News: